Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 25, 2026, 9:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Ann Arbor, Michigan Clear all
Completed Phase 2 Interventional Results available

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

NCT03633331
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, HER2/Neu Negative, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Palbociclib, Letrozole, Fulvestrant, Questionnaire Administration, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
70 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
447
States / cities
Anchorage, Alaska • Kingman, Arizona • Arroyo Grande, California + 303 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jul 25, 2026, 9:03 AM EDT
Recruiting Not applicable Interventional

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

NCT03723928
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29
Interventions
Usual care disease monitoring, Serum Tumor Marker directed disease monitoring, Quality-of-Life Assessment, Anxiety Questionnaire Administration
Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
739 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2036
U.S. locations
709
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 456 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Jul 25, 2026, 9:03 AM EDT
Completed Phase 3 Interventional Results available

Self-Management Addressing Heart Disease Risk Trial

NCT00499096
View directory record Official record
Conditions
Bipolar Disorder, Cardiovascular Disease
Interventions
Chronic care model for Bipolar Disorder
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 19, 2014 · Synced Jul 25, 2026, 9:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Trans-MAPP II Study of Urologic Chronic Pelvin Pain

NCT02898220
View directory record Official record
Conditions
Interstitial Cystitis, Chronic Prostatitis
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
6
States / cities
Los Angeles, California • Chicago, Illinois • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Jul 25, 2026, 9:03 AM EDT
Completed Phase 2 Interventional

Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma

NCT00026520
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
recombinant interferon alfa, thalidomide
Biological · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
94
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced Jul 25, 2026, 9:03 AM EDT
Recruiting Phase 3 Interventional

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

NCT07198074
View directory record Official record
Conditions
Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma
Interventions
Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
232
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 183 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 25, 2026, 9:03 AM EDT
Active, not recruiting Phase 2 Interventional

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

NCT04164082
View directory record Official record
Conditions
Bladder Flat Urothelial Carcinoma In Situ, Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Cystoscopy, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Pembrolizumab, Transurethral Resection of Bladder Tumor
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
382
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 258 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jul 25, 2026, 9:03 AM EDT
Completed Phase 3 Interventional

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Older Patients With Non-Hodgkin's Lymphoma

NCT00003150
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, CHOP regimen, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
60 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2006
U.S. locations
91
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Jul 25, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)

NCT02301143
View directory record Official record
Conditions
Pancreatic Neoplasms
Interventions
nab-Paclitaxel, Gemcitabine, Chemoradiation, Capecitabine, Surgery
Drug · Procedure
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
23
States / cities
Scottsdale, Arizona • Sacramento, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Jul 25, 2026, 9:03 AM EDT
Completed Phase 2 Interventional

Chemotherapy Followed by Radiation Therapy in Treating Adults With Supratentorial Glioma

NCT00002806
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
lomustine, procarbazine hydrochloride, vincristine sulfate, low-LET photon therapy
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2004
U.S. locations
17
States / cities
Scottsdale, Arizona • Urbana, Illinois • Cedar Rapids, Iowa + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Jul 25, 2026, 9:03 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy After Surgery in Treating Patients With Cancer of the Esophagus or Stomach

NCT00003237
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
cisplatin, paclitaxel, surgical procedure
Drug · Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
28
States / cities
Chicago, Illinois • Evanston, Illinois • Peoria, Illinois + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Jul 25, 2026, 9:03 AM EDT
Recruiting Not applicable Interventional

Adjunctive Motivational Alcohol Intervention to Prevent IPV

NCT05287711
View directory record Official record
Conditions
Alcohol Use and Intimate Partner Violence
Interventions
Motivational Enhancement Therapy, Alcohol Education Control, Treatment as Usual, Strength at Home
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Jul 25, 2026, 9:03 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer

NCT00003834
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
fluorouracil, leucovorin calcium, oxaliplatin
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
20
States / cities
Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2016 · Synced Jul 25, 2026, 9:03 AM EDT
Terminated No phase listed Observational

A Study to Establish a New Onset Hyperglycemia and Diabetes Cohort

NCT03731637
View directory record Official record
Conditions
Diabetes, Type2 Diabetes, Diabetes Mellitus
Interventions
Not listed
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
50 Years to 85 Years
Enrollment
2,269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
18
States / cities
Los Angeles, California • Oakland, California • Palo Alto, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Jul 25, 2026, 9:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluating a Preference-based Intervention for Increasing Colorectal Cancer Screening

NCT00810771
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Standard Information, Preference-tailored Information
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
50 Years to 78 Years
Enrollment
466 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
2
States / cities
Ann Arbor, Michigan • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Jul 25, 2026, 9:03 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clostridium Difficile Vaccine Efficacy Trial

NCT03090191
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Clostridium difficile vaccine, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
17,535 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
220
States / cities
Athens, Alabama • Huntsville, Alabama • Mobile, Alabama + 145 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2023 · Synced Jul 25, 2026, 9:03 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

NCT00658814
View directory record Official record
Conditions
Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With Maturation, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21)(q22;q22.1); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-KMT2A, Adult Acute Myeloid Leukemia Without Maturation, Adult Acute Myelomonocytic Leukemia, Adult Erythroleukemia, Adult Pure Erythroid Leukemia, Secondary Acute Myeloid Leukemia
Interventions
Azacitidine, Gemtuzumab Ozogamicin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
60 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2027
U.S. locations
177
States / cities
Burbank, California • Palo Alto, California • Sacramento, California + 122 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 25, 2026, 9:03 AM EDT
Terminated Phase 2 Interventional

S9903: Whole Brain Radiotherapy Followed By Stereotactic Radiosurgery for Limited Malignant Melanoma Brain Metastases

NCT00003911
View directory record Official record
Conditions
Melanoma (Skin), Metastatic Cancer
Interventions
stereotactic radiosurgery
Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
86
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Jul 25, 2026, 9:03 AM EDT
Completed Phase 2 Interventional

Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia

NCT00005609
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab
Biological
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
66
States / cities
Scottsdale, Arizona • Duarte, California • Palo Alto, California + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2013 · Synced Jul 25, 2026, 9:03 AM EDT
Completed Phase 2 Interventional

Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus

NCT00003864
View directory record Official record
Conditions
Esophageal Cancer
Interventions
carboplatin, docetaxel
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
71
States / cities
Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Jul 25, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Results available

S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

NCT02562716
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma
Interventions
Fluorouracil, Gemcitabine Hydrochloride, Irinotecan Hydrochloride, Oxaliplatin, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Pancreatectomy
Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 75 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
807
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 515 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Jul 25, 2026, 9:03 AM EDT
Terminated Phase 3 Interventional Results available

Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

NCT02927249
View directory record Official record
Conditions
Node Positive HER2 Negative Breast Cancer
Interventions
Placebo, Aspirin
Other · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 69 Years
Enrollment
3,021 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1426
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 902 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Jul 25, 2026, 9:03 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer

NCT07091617
View directory record Official record
Conditions
Miscellaneous Neoplasm, Nos, Non-Neoplastic Condition, Nos
Interventions
Telemedicine, Genetic Testing, Internet-Based Intervention, Educational Intervention, Patient Navigation, Interview, Survey Administration
Other · Behavioral
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
535 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
280
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 201 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 25, 2026, 9:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Enhancing Quality of Informed Consent (EQUIC-DP) Developmental Phase

NCT00032552
View directory record Official record
Conditions
Informed Consent
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Enrollment
632 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2006
U.S. locations
18
States / cities
Birmingham, Alabama • Palo Alto, California • Melbourne, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2010 · Synced Jul 25, 2026, 9:03 AM EDT